313339-35-4

Usage

Uses

Used in Pharmaceutical Industry:
4,6-DICHLORO-2-(METHYLTHIO)PYRIMIDINE-5-CARBOXYLIC ACID is used as an intermediate in the synthesis of pharmaceuticals for its potential antimicrobial and antifungal properties. It contributes to the development of new drugs by providing a versatile chemical structure that can be modified to enhance therapeutic effects.
Used in Agrochemical Industry:
In the agrochemical sector, 4,6-DICHLORO-2-(METHYLTHIO)PYRIMIDINE-5-CARBOXYLIC ACID is utilized as an intermediate in the synthesis of agrochemicals. Its potential antimicrobial and antifungal properties make it a valuable component in the creation of pesticides and fungicides to protect crops and enhance agricultural productivity.
Used in Organic Chemistry Research:
4,6-DICHLORO-2-(METHYLTHIO)PYRIMIDINE-5-CARBOXYLIC ACID is used as a building block in the field of organic chemistry. Its unique structural properties allow for the development of various biologically active compounds, making it an essential component in the synthesis of novel chemical entities with potential applications in medicine and other fields.

InChI:InChI=1/C6H4Cl2N2O2S/c1-13-6-9-3(7)2(5(11)12)4(8)10-6/h1H3,(H,11,12)

Upstream product

• 6299-25-8 4,6-Dichloro-2-(methylthio)pyrimidine 
• 124-38-9 carbon dioxide 
• 1979-98-2 4,6-dihydroxy-2-methylmercaptopyrimidine 
• 33097-11-9 4,6-dichloro-2-methylsulfanylpyrimidine-5-carboxyaldehyde 

Downstream Products

• 883870-28-8 methyl 4,6-dichloro-2-methylthiopyrimidine-5-carboxylate 
• 1092114-79-8 (S)-N-(1-tert-butoxycarbonylpyrrolidin-2-ylmethyl)-4,6-dichloro-N-[3-(4-methyl-5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)phenyl]-2-methylthiopyrimidine-5-carboxamide 
• 959070-42-9 4,6-dichloro-2-(methylthio)pyrimidine-5-carboxylic acid ethyl ester 
• 1269119-30-3 benzyl 4-chloro-5-hydroxy-7-methyl-2-(methylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylate 
• 1269119-34-7 benzyl 4-chloro-7-methyl-5-(1-methylethoxy)-2-(methylsulfanyl)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylate 
• 1269119-37-0 benzyl 7-methyl-5-(1-methylethoxy)-2-(methylsulfanyl)-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-6-carboxylate 
• 1269119-32-5 C₁₈H₂₀ClN₃O₄S 
• 1394002-56-2 methyl (trans-4-{4-[(2-{[tert-butyl(dimethyl)silyl]oxy}ethyl){[4,6-dichloro-2-(methylsulfanyl)-pyrimidin-5-yl]carbonyl}amino]phenyl}cyclohexyl)acetate 
• 569684-16-8 6-[3,5-bis(trifluoromethyl)phenylmethyl]-4-(2-methylphenyl)-2-methanesulfonyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-one 
• 569684-04-4 6-[3,5-bis(trifluoromethyl)phenylmethyl]-4-(2-methylphenyl)-2-methylthio-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-one 
• 569683-98-3 6-[3,5-bis(trifluoromethyl)benzyl]-4-chloro-2-methylthio-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-one 
• 606971-30-6 2-(4-acetylpiperazine-1-yl)-6-[3,5-bis(trifluoromethyl)benzyl]-5,6,7,8,9,10-hexahydro-4-(2-methylphenyl)-5-oxopyrimido[4,5-b][1,5]diazocine 

Relevant academic research and scientific papers

BICYCLIC CARBOXAMIDE INHIBITORS OF KINASES

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein X1, X2, X3, X4, R1, R2, R3, A, B, Z, n, and m are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as ALK and methods of treating diseases such as cancer.

FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF

The present invention provides a fused heterocycle derivative having a strong Smo inhibitory activity, and use thereof. Specially, the present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or salt thereof, and a medicament containing the compound or a prodrug thereof, which is an Smo inhibitor or an agent for the prophylaxis or treatment of cancer.

PYRIMIDODIAZEPINONE DERIVATIVE

The invention provides a pyrimidodiazepinone derivative represented by the general formula (I) [wherein n represents 1 or 2, Z represents a hydrogen atom or the like, R1 and R2 may be the same or different, and each represents a hydrogen atom or the like, A represents a bond, (CH2)m (wherein m represents an integer of 1 to 4), optionally substituted phenylene, optionally substituted pyridinediyl, or C=O, R3 represents a hydrogen atom, optionally substituted lower alkyl, or the like, and R4 represents a hydrogen atom or the like], or a pharmaceutically acceptable salt thereof or the like.

4-Amino-2-cyanopyrimidines: Novel scaffold for nonpeptidic cathepsin S inhibitors

We describe here a novel 4-amino-2-cyanopyrimidine scaffold for nonpeptidomimetic cathepsin S selective inhibitors. Some of the synthesized compounds have sub-nanomolar potency and high selectivity toward cathepsin S along with promising pharmacokinetic a

ALICYCLIC HETEROCYCLIC COMPOUND

An alicyclic heterocyclic compound represented by the following formula or a pharmaceutically acceptable salt thereof: wherein ring A is a heterocyclic ring, ring B is a carbocyclic ring, a heterocyclic ring etc., P1 and P2 are CH or N, q and r are 0 to 2, X is -NH-, -O-, -CH2-, etc., Y is -CH2-, -CO-, -SO2-, etc., Z is -CO-, -SO2-, etc., and R3 is carbocyclic group, heterocyclic group, hydroxyl, alkoxy or amino, is useful as a controlling agent of the function of CCR4 useful for the prevention or treatment for bronchial asthma, atopic dermatitis, etc.

2-Substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5] oxazocin-5-one as a structurally new NK1 antagonist

The structurally novel pyrimido[4,5-b][1,5]oxazocine derivative 3, a hybrid compound of pyrido[4,3-b]- and [2,3-b]-1,5-oxazocine (1 and 2, respectively), was designed and synthesized. We examined the atropisomeric property and the NK1 antagonis

Design, synthesis, and evaluation of novel 2-substituted-4-aryl-6,7,8,9- tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-ones as NK1 antagonists

A series of novel bicyclic pyrimidine derivatives was prepared as part of a search for NK1 antagonist aimed at the treatment of urinary incontinence. Among them, 3g, a pyrimido[4,5-b][1,5]oxazocine derivative, bearing a 4-acetylpiperazinyl grou

FUSED BICYCLIC PYRIMIDINE DERIVATIVES

A novel fused bicyclic pyrimidine derivative or a salt thereof that acts as a tachykinin receptor antagonist and, in particular, as an NK1 receptor antagonist is represented by the following general formula (1): wherein the rings A and B are each a benzen

Cyclic compounds

1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, wherein X is ═CH— or ═N—, Y is —NH—, —NR4—, —S—, —O—, —CH═N—, —N═CH—, —N═N—, —CH═CH—, etc., R1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R3 and a substituent in Y may be combined to form a lactone ring. The compound of the present invention has excellent selective PDE V inhibitory activity and therefore, is useful as a therapeutic or prophylactic drug for treating various diseases due to functional disorders on cGMP-signaling.

FUSED BICYCLIC PYRIMIDINE DERIVATIVES

A novel fused bicyclic pyrimidine derivative or a salt thereof that acts as a tachykinin receptor antagonist and, in particular, as an NK1 receptor antagonist is represented by the following general formula (1): wherein the rings A and B are each a benzene ring having 1 to 3 substituents (any adjacent two of which may be bound to one another to form a ring); the ring C is a nitrogen-containing ring; m is 1 or 2; and n is 2 or 3.